Search results for "ISPH"

showing 10 items of 819 documents

Non-Radiation Based Early Pain Relief Treatment Options for Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain: A Systematic Review

2020

Introduction: Cancer induced bone pain (CIBP) is frequent in patients with non-small cell lung cancer (NSCLC). Radiation therapy continues to be the gold standard for treatment of painful bone metastases, however only a limited number of metastases can be irradiated. We evaluated non-radiation based early CIBP relief options in NSCLC through a systematic review. Methods: Systematic review including all prospective articles published between 01-1994 and 06-2020 on Pubmed, Cochrane Library and ClinicalTrials.gov database. Inclusion: nonradiation based trials evaluating CIBP early pain relief options (initially defined as pain score evaluated within two weeks, because of no randomized trials, …

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentPain reliefcancer induced bone painCochrane Librarylcsh:RC254-282DISEASEpain relieflaw.inventionPALLIATIVE RADIOTHERAPY03 medical and health sciences0302 clinical medicineRandomized controlled trialSDG 3 - Good Health and Well-beingbone metastasessystematic reviewlawQUALITY-OF-LIFEInternal medicinemedicineLung cancerBone painIBANDRONATEbisphosphonatesnon-small cell lung cancerDENOSUMABbusiness.industryGold standardCancermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensEFFICACYRadiation therapy1ST-LINE TREATMENT030104 developmental biologyMETASTASESOncology030220 oncology & carcinogenesisZOLEDRONIC ACIDmedicine.symptombusinessFrontiers in Oncology
researchProduct

Acute Cortical Transhemispheric Diaschisis after Unilateral Traumatic Brain Injury

2017

Focal neocortical brain injuries lead to functional alterations, which can spread beyond lesion-neighboring brain areas. The undamaged hemisphere and its associated disturbances after a unilateral lesion, so-called transhemispheric diaschisis, have been progressively disclosed over the last decades; they are strongly involved in the pathophysiology and, potentially, recovery of brain injuries. Understanding the temporal dynamics of these transhemispheric functional changes is crucial to decipher the role of the undamaged cortex in the processes of functional reorganization at different stages post-lesion. In this regard, little is known about the acute-subacute processes after 24-48 h in th…

0301 basic medicinePatch-Clamp TechniquesTraumatic brain injurySomatosensory system03 medical and health sciences0302 clinical medicineCortex (anatomy)Unilateral lesionBrain Injuries TraumaticNeuroplasticitymedicineAnimalsDiaschisisNeuronal PlasticityMotor CortexElectroencephalographySomatosensory Cortexmedicine.diseaseMice Inbred C57BLDisease Models AnimalElectrophysiology030104 developmental biologymedicine.anatomical_structureBrain HemisphereNeurology (clinical)PsychologyNeuroscience030217 neurology & neurosurgeryJournal of Neurotrauma
researchProduct

The impact of the 2015/2016 El Niño on global photosynthesis using satellite remote sensing

2018

The El Niño-Southern Oscillation exerts a large influence on global climate regimes and on the global carbon cycle. Although El Niño is known to be associated with a reduction of the global total land carbon sink, results based on prognostic models or measurements disagree over the relative contribution of photosynthesis to the reduced sink. Here, we provide an independent remote sensing-based analysis on the impact of the 2015–2016 El Niño on global photosynthesis using six global satellite-based photosynthesis products and a global solar-induced fluorescence (SIF) dataset. An ensemble of satellite-based photosynthesis products showed a negative anomaly of −0.7 ± 1.2 PgC in 2015, but a sli…

0301 basic medicineRainforest010504 meteorology & atmospheric sciencesRainforestPhotosynthesisAtmospheric sciences01 natural sciencesFluorescenceGeneral Biochemistry Genetics and Molecular BiologySink (geography)Carbon cycle03 medical and health sciencesPhotosynthesis0105 earth and related environmental sciencesEl Nino-Southern OscillationTropical ClimategeographyCarbon dioxide in Earth's atmospheregeography.geographical_feature_categoryMoistureNorthern HemisphereCarbon sinkArticlesGrassland030104 developmental biologyRemote Sensing TechnologySunlightEnvironmental scienceGeneral Agricultural and Biological SciencesPhilosophical Transactions of the Royal Society B: Biological Sciences
researchProduct

Reverse screening on indicaxanthin from Opuntia ficus-indica as natural chemoactive and chemopreventive agent

2018

Indicaxanthin is a bioactive and bioavailable betalain pigment extracted from Opuntia ficus indica fruits. Indicaxanthin has pharmacokinetic proprieties, rarely found in other phytochemicals, and it has been demonstrated that it provides a broad-spectrum of pharmaceutical activity, exerting anti-proliferative, anti-inflammatory, and neuromodulator effects. The discovery of the Indicaxanthin physiological targets plays an important role in understanding the biochemical mechanism. In this study, combined reverse pharmacophore mapping, reverse docking, and text-based database search identified Inositol Trisphosphate 3-Kinase (ITP3K-A), Glutamate carboxypeptidase II (GCPII), Leukotriene-A4 hydr…

0301 basic medicineStatistics and ProbabilityMolecular dynamicPyridinesKainate receptorIndicaxanthinPhytochemical01 natural sciencesGeneral Biochemistry Genetics and Molecular BiologyDocking03 medical and health scienceschemistry.chemical_compoundNeoplasmsGlutamate carboxypeptidase IIData MiningHumansEnzyme InhibitorsMM-GBSAPharmacophore modelingBinding SitesGeneral Immunology and MicrobiologyReverse screening010405 organic chemistryAnti-cancerApplied MathematicsPhosphodiesteraseOpuntiaPhosphoserine phosphataseInositol trisphosphateGeneral MedicineAntineoplastic Agents Phytogenic0104 chemical sciencesBetaxanthinsNeoplasm ProteinsNeuromodulatorMolecular Docking SimulationAnti-inflammatory agent030104 developmental biologychemistryBiochemistryDocking (molecular)Modeling and SimulationPharmacophoreGeneral Agricultural and Biological SciencesIndicaxanthin
researchProduct

Drugs and diseases: Summary and consensus statements of group 1. The 5th EAO Consensus Conference 2018

2018

OBJECTIVES: The task of this working group was to update the knowledge about the use of drugs and biologicals affecting healing of soft tissue and bone during implant treatment or procedures associated with it. Moreover, the impact of titanium particles and biocorrosion on complications and implant survival has been analysed. MATERIALS AND METHODS: The literature in the areas of interest (platelet concentrates, antiresorptive drugs as well as implant-host interaction) was screened using systematic reviews for the former two areas, whereas a narrative critical review was performed for the latter topic. Two manuscripts on platelet concentrates, one manuscript on antiresorptive drugs and one m…

0301 basic medicineTechnologymedicine.medical_specialtymedication-related osteonecrosis of the jawsplatelet-rich fibrin610 Medicine & healthOdontologi03 medical and health sciencesEngineering0302 clinical medicinesystematic reviewguided bone regeneration sinus floor elevationdental implantsDentistry Oral Surgery & Medicinemedicineantiresorptive drugstitanium610 Medicine & healthEngineering BiomedicalbisphosphonatesScience & Technologycorrosionbusiness.industryConsensus conferenceimplant therapyplatelet-rich plasma030206 dentistryddc:617.63. Good healthhormone replacement therapyAntiresorptive Drugs030104 developmental biologySystematic reviewGroup analysisDentistryFamily medicinealveolar ridge preservationOral SurgerybusinessLife Sciences & Biomedicineperi-implantitisClinical Oral Implants Research
researchProduct

Evaluation of Safety and Dosimetry of 177Lu-DOTA-ZOL for Therapy of Bone Metastases

2021

Palliative treatment of bone metastasis using radiolabeled bisphosphonates is a well-known concept proven to be safe and effective. A new therapeutic radiopharmaceutical for bone metastasis is 177Lu-DOTA-zoledronic acid (177Lu-DOTA-ZOL). In this study, the safety and dosimetry of a single therapeutic dose of 177Lu-DOTA-ZOL were evaluated on the basis of a series of SPECT/CT images and blood samples. Methods: Nine patients with exclusive bone metastases from metastatic castration-resistant prostate cancer (mCRPC) (70.8 ± 8.4 y) and progression under conventional therapies participated in this prospective study. After receiving 5,780 ± 329 MBq 177Lu-DOTA-ZOL, patients underwent 3-dimensional …

0301 basic medicinebusiness.industrymedicine.medical_treatmentBone metastasisBisphosphonatemedicine.disease03 medical and health sciencesProstate cancer030104 developmental biology0302 clinical medicineTherapeutic index030220 oncology & carcinogenesisRadionuclide therapymedicineDosimetryRadiology Nuclear Medicine and imagingNuclear medicinebusinessProspective cohort studyBlood drawingJournal of Nuclear Medicine
researchProduct

Bisphenolic compounds alter gene expression in MCF-7 cells through interaction with estrogen receptor α

2020

Plasticizers released from microplastic are increasingly viewed with concern. While adverse health effects induced by bisphenol A and its analogues on marine animals are well documented in the literature, the endocrine potential of bisphenolic compounds on human health remains elusive. We applied next generation sequencing (NGS) with the estrogen receptor α (ERα) positive human breast cancer cell line MCF-7 treated with 17-β-estradiol (E2), bisphenol A (BPA), bisphenol B (BPB), bisphenol Z (BPZ) and tetramethyl bisphenol A (4MeBPA). We used molecular docking, microscale thermophoresis, ERα activation assay, and cell cycle experiments on MCF-7 and ERα overexpressing HEK293 cells to verify th…

0301 basic medicineendocrine systemBisphenolDown-RegulationGene ExpressionEstrogen receptorBreast NeoplasmsEndocrine DisruptorsToxicologyCell Line03 medical and health sciences0302 clinical medicinePhenolsPlasticizersBCAS3Cell Line TumorHumansBenzhydryl CompoundsCell ProliferationInsulin-like growth factor 1 receptorPharmacologyEstradiolChemistryCell growthEstrogen Receptor alphaEstrogensCell cycleUp-RegulationHEK293 Cells030104 developmental biologyPRKCDMCF-7030220 oncology & carcinogenesisMCF-7 CellsCancer researchFemalehormones hormone substitutes and hormone antagonistsSignal TransductionToxicology and Applied Pharmacology
researchProduct

Regulatory identification of BPA as an endocrine disruptor : Context and methodology

2018

International audience; BPA is one of the most investigated substances for its endocrine disruptor (ED) properties and it is at the same time in the center of many ED-related controversies, the analysis on how BPA fits to the regulatory identification as an ED is a challenge in terms of methodology. It is also a great opportunity to test the regulatory framework with a uniquely data-rich substance and learn valuable lessons for future cases. From this extensive database, it was considered important to engage in a detailed analysis so as to provide specific and strong evidences of ED while reflecting accurately the complexity of the response as well the multiplicity of adverse effects. An ap…

0301 basic medicineendocrine systemBrain developmentpertubateur endocrinienEndocrine disruptionContext (language use)Computational biologyMESH: Social Control Formal010501 environmental sciencesBiologyEndocrine Disruptors01 natural sciencesBiochemistryMammary gland developmentbisphenol A;endocrine disruption;ED;SVHC;substance of very high concern;REACh03 medical and health sciencesEndocrinologyBisphenol AMESH: PhenolsPhenolsSubstance of very high concernMESH: Benzhydryl CompoundsFood and Nutritionbisphénol aAnimalsHumansBenzhydryl CompoundsMolecular BiologyComputingMilieux_MISCELLANEOUSSVHC0105 earth and related environmental sciencesEndocrinology and metabolismurogenital systemsubstance toxiqueED3. Good healthSocial Control FormalMESH: Endocrine Disruptors030104 developmental biologyEndocrine disruptor[SDV.TOX]Life Sciences [q-bio]/ToxicologyAlimentation et NutritionEndocrinologie et métabolismeREACHIdentification (biology)
researchProduct

Treatments for post-menopausal osteoporotic women, what's new? How can we manage long-term treatment?

2016

Since the mid-1980s, postmenopausal osteoporosis (PMO) has been considered a serious public health concern because of the associated fractures. Pharmacological therapies that effectively reduce the number of fractures by improving bone mass have been and are being developed continuously. Most current agents inhibit bone loss by reducing bone resorption, but emerging therapies may increase bone mass by stimulating bone formation. Furthermore, nowadays, the most representative pharmaceuticals have been prescribed long enough to include the reporting of some adverse effects. This review discusses osteoporotic drugs that are approved or are under investigation for the treatment of post-menopaus…

0301 basic medicinemedicine.medical_specialtyLong term treatmentTime Factorsmedicine.medical_treatmentRomosozumab030209 endocrinology & metabolismPostmenopausal osteoporosisBone resorption03 medical and health sciences0302 clinical medicinemedicineHumansIntensive care medicineAdverse effectOsteoporosis PostmenopausalPharmacologybusiness.industryPublic healthBisphosphonateSurgery030104 developmental biologyDenosumabFemalebusinessmedicine.drugEuropean journal of pharmacology
researchProduct

Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy

2021

Summary The use of buffered soluble alendronate 70 mg effervescent tablet, a convenient dosing regimen for bisphosphonate therapy, seems a cost-effective strategy compared with relevant alternative treatments for postmenopausal women with osteoporosis aged 60 years and over in Italy. Introduction To assess the cost-effectiveness of buffered soluble alendronate (ALN) 70 mg effervescent tablet compared with relevant alternative treatments for postmenopausal osteoporotic women in Italy. Methods A previously validated Markov microsimulation model was adjusted to the Italian healthcare setting to estimate the lifetime costs (expressed in €2019) per quality-adjusted life-years (QALY) of buffered …

0301 basic medicinemedicine.medical_specialtyeconomic evaluationCost effectivenessCost-Benefit AnalysisEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisUrology030209 endocrinology & metabolismAlendronate . Buffered soluble alendronate . Cost-effectiveness . Economic evaluation . Effervescent tablets . Osteoporosis . TreatmentAlendronate; Buffered soluble alendronate; Cost-effectiveness; Economic evaluation; Effervescent tablets; Osteoporosis; Treatment; Aged; Alendronate; Cost-Benefit Analysis; Female; Humans; Italy; Middle Aged; Observational Studies as Topic; Postmenopause; Quality-Adjusted Life Years; Tablets; Bone Density Conservation Agents; Osteoporosis; Osteoporosis Postmenopausal03 medical and health sciences0302 clinical medicinemedicineHumansEffervescent tabletOsteoporosis PostmenopausalAgedBone mineralPostmenopausal womenBone Density Conservation AgentstreatmentAlendronatebusiness.industrybuffered soluble alendronateMiddle AgedBisphosphonatemedicine.diseaseosteoporosisPostmenopauseObservational Studies as TopicDenosumabZoledronic acidItalyeffervescent tabletsPostmenopausalFemaleOriginal ArticleCost-effectivenessQuality-Adjusted Life Years030101 anatomy & morphologybusinessTabletsmedicine.drugOsteoporosis International
researchProduct